Join to View Full Profile
200 1st St SwRochester, MN 55905
Phone+1 507-284-2511
Dr. Block is on Doximity
As a Doximity member you'll join over two million verified healthcare professionals in a private, secure network.
- Gain access to free telehealth tools, such as our “call shielding” and one-way patient texting.
- Connect with colleagues in the same hospital or clinic.
- Read the latest clinical news, personalized to your specialty.
Education & Training
Mayo Clinic College of Medicine and Science (Rochester)Fellowship, Hematology and Medical Oncology, 2008 - 2011- Mayo Clinic College of Medicine and Science (Rochester)Residency, Internal Medicine, 2005 - 2008
- Mayo Clinic College of MedicineClass of 2005
Certifications & Licensure
MN State Medical License 2006 - 2026
American Board of Internal Medicine Internal Medicine- American Board of Internal Medicine Medical Oncology
Clinical Trials
- Vaccine Therapy and Cyclophosphamide in Treating Patients With Stage II-III Breast or Stage II-IV Ovarian, Primary Peritoneal, or Fallopian Tube Cancer Start of enrollment: 2012 Jul 24
- Vaccine Therapy for Patients With Stage IIIC-IV Ovarian Epithelial, Fallopian Tube, or Primary Peritoneal Cavity Cancer Start of enrollment: 2014 Apr 14
Publications & Presentations
PubMed
- ASO Visual Abstract: Accuracy of PET-CT to Assess the Extent of Nodal Disease in Patients with Clinical Stage III Melanoma Following Neoadjuvant Treatment.Ronen Stoff, Mariana Yalon, Matthew P Thorpe, Thomas J Flotte, Matthew S Block
Annals of Surgical Oncology. 2025-09-16 - NeoACTIVATE Arm C: Phase II trial of neoadjuvant atezolizumab and tiragolumab for high-risk operable Stage III melanoma.Tina J Hieken, David Zahrieh, Thomas J Flotte, Roxana S Dronca, Evidio Domingo-Musibay
European Journal of Cancer. 2025-09-09 - ASO Author Reflections: Is PET/CT Response Assessment After Neoadjuvant Systemic Therapy for Stage III Melanoma Enough?Ronen Stoff, Matthew S Block, Tina J Hieken
Annals of Surgical Oncology. 2025-08-29
Press Mentions
Clinical Trials: A Significant Part of Cancer CareMay 1st, 2025- What You Should Know About Ovarian Cancer VaccinesNovember 16th, 2024
- Transgene and NEC Announce Positive Preliminary Data from Phase I Studies of TG4050, a Novel Individualized Neoantigen Cancer VaccineNovember 22nd, 2021
- Join now to see all
Grant Support
- A phase I/II study of combined therapy with Th17-inducing dendritic cells and pembrolizumab in patients with recurrent epithelial ovarian cancerMAYO CLINIC JACKSONVILLE2023–2028
- A Novel Melanoma Vaccine Based on a Shared Neoantigen and a Liquid Polymer PlatformTREKKA THERAPEUTICS, LLC2023–2025
Professional Memberships
- Member
Viewing the full profile is available to verified healthcare professionals only.
Find your profile and take control of your online presence:
